Tirzepatide helps with liver fat, but the glucagon-mediated effect in retatrutide is in a different category entirely
These warnings, as well as knowledge of the negative secondary ocular outcomes in the large diabetes clinical trials, likely play a role in the referrals to eye clinics for retinal examinations from internists
Based on the profile of participants enrolled in retatrutide trials to date, the drug appears most relevant to adults living with obesity (BMI 30 kg/m) or those who are overweight (BMI 27 kg/m) with weight-related health conditions such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea
Journal of the Endocrine Society, 7 (4), bvad016
People who take the maximum dose of an injected GLP-1 drug can lose around 20 percent of their body weight, Tan notes much more than what this trial found for the maximum dose of the GLP-1 pill
we acknowledge the lack of any widely accepted terminology to describe this new class of obesity medications)